Solid Biosciences (SLDB) Operating Income: 2017-2024
Historic Operating Income for Solid Biosciences (SLDB) over the last 7 years, with Dec 2024 value amounting to -$39.9 million.
- Solid Biosciences' Operating Income fell 79.19% to -$39.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$129.7 million, marking a year-over-year decrease of 24.44%. This contributed to the annual value of -$129.7 million for FY2024, which is 24.44% down from last year.
- Solid Biosciences' Operating Income amounted to -$39.9 million in Q4 2024, which was down 13.40% from -$35.2 million recorded in Q3 2024.
- Over the past 5 years, Solid Biosciences' Operating Income peaked at -$19.0 million during Q2 2020, and registered a low of -$39.9 million during Q4 2024.
- Over the past 3 years, Solid Biosciences' median Operating Income value was -$26.9 million (recorded in 2024), while the average stood at -$28.6 million.
- As far as peak fluctuations go, Solid Biosciences' Operating Income skyrocketed by 35.59% in 2023, and later plummeted by 79.19% in 2024.
- Solid Biosciences' Operating Income (Quarterly) stood at -$21.3 million in 2020, then reached -$34.6 million in 2022, then surged by 35.59% to -$22.3 million in 2023, then crashed by 79.19% to -$39.9 million in 2024.
- Its last three reported values are -$39.9 million in Q4 2024, -$35.2 million for Q3 2024, and -$27.8 million during Q2 2024.